|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1650 AUD | +3.12% |
|
+3.12% | -2.94% |
| 10/07 | Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial | MT |
| 03/07 | Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Neutral |
| Resistance | 0.175 | 0.175 | 0.225 |
| Spread/Res. | -5.71% | -5.71% | -26.67% |
| Spread/Supp. | +10.00% | +22.22% | +57.14% |
| Support | 0.15 | 0.135 | 0.105 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- NUZ Stock
- Charts Neurizon Therapeutics Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition